A comparative study to assess the efficacy and safety of bepotastine and cetirizine in allergic rhinitis


  • A. T. Priyanka Department of Pharmacology, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India
  • K. R. Mamatha Department of Pharmacology, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India
  • G. M. Puttamadaiah Department of ENT, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India




Rhinitis, Cetirizine, Bepotastine


Background: Pharmacotherapy is the mainstay of allergic rhinitis and many caregivers use over-the-counter antihistamines. Bepotastine is a novel oral second generation non-sedative antihistamine and an effective treatment option for allergic rhinitis. The objectives of the present study were to evaluate the efficacy and safety of bepotastine versus cetirizine an over the counter drug.

Methods: A prospective, randomized, open-label, parallel-group study was conducted among 60 patients fulfilling the inclusion and exclusion criteria. Group A (n=30) received tablet cetirizine 10 mg once daily and Group B (n=30) received tablet bepotastine 10 mg once daily. Efficacy was assessed by mean change in total symptom score (TSS) which is the sum of total nasal symptom score and total ocular symptom score at the end of two weeks from baseline.

Results: At the end of two weeks of treatment, both groups showed statistically significant (p<0.005) improvements from their baseline TSS. Mean TSS was reduced from12.36±2.12 to 4.2±1.66 in group A and from 13.33±3.039 to 3.033±1.40 in Group B. Significant statistical difference in TSS was seen more in Group B than Group A (p<0.005).

Conclusions: Both the groups showed a substantial therapeutic benefit in patients with allergic rhinitis, however bepotastine is more effective.



Varshney J, Varshney H. Allergic rhinitis: an overview. Indian J Otolaryngol Head Neck Surg. 2015;67(2):143-9.

Kankaanranta H, Kauppi P, Tuomisto LE, Ilmarinen P. Emerging comorbidities in adult asthma: risks, clinical associations, and mechanisms. Mediator Inflammat. 2016;2016:3690628.

Recto MT, Gabriel MT, Kulthanan K, Tantilipikorn P, Aw DC, Lee TH, et al. Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia. Clin Mol Allerg. 2017;15:19.

Cheng KC, Hsu JY, Fu LS, Chang WC, Chu JJ, Chi CS. Influence of cetirizine and loratadine on granulocyte- macrophage colony-stimulating factor and interleukin-8 release in A549 human airway epithelial cells stimulated with interleukin-1beta. J Microbiol Immunol Infect. 2006;39(3):206-11.

Godse K, Kumari N. Bepotastine besilate: a novel anti-histamine. Indian J Drugs Dermatol. 2017;3:64-8.

Okubo TFK. Effectiveness of second-generation antihistamine for the treatment of morning symptoms observed in patients with perennial allergic rhinitis: comparison study of bepotastine besilate versus olopatadine hydrochloride. Otorhinolaryngol. 2015;05(2):1000185.

Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007;28(1):3-9.

Hoyte FCL, Nelson HS. Recent advances in allergic rhinitis. F1000Res. 2018;7: F1000 Faculty Rev-1333.

Lalitha A, Mamatha KR, Puttamadaiah GM. Azelastine hydrochloride nasal spray and its combination with fluticasone propionate in the management of allergic rhinitis- a comparative study. Nat J Physiol Pharm Pharmacol. 2019;9(5):356-60.

Small P, Keith PK, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2018;14(2):51.

Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.

Rotiroti D, De Sarro GB, Musolino R, Nistico G. 1983. A new model of experimental epilepsy: the cephazolin-induced epilepsy. In: Nistico G, Di Perri R, Meinardi H, eds. Epilepsy, an update of research

and therapy. New York: Alan R. Liss, Inc.; 129–144.

Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002;89(5):479-84.

Zhang L, Cheng L, Hong J. The clinical use of cetirizine in the treatment of allergic rhinitis. Pharmacol. 2013;92:14-25.

Canonica GW, Blaiss M. Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J. 2011;4(2):47-53.

Deshmukh S, Narayanan V, Bhargava A. Efficacy and safety of bepotastine, a newer 2 nd generation antihistamine, compared to fexofenadine in allergic rhinitis. World J Pharm Med Res. 2018;4(9):186-90.




How to Cite

Priyanka, A. T., Mamatha, K. R., & Puttamadaiah, G. M. (2019). A comparative study to assess the efficacy and safety of bepotastine and cetirizine in allergic rhinitis. International Journal of Basic & Clinical Pharmacology, 8(10), 2304–2308. https://doi.org/10.18203/2319-2003.ijbcp20194276



Original Research Articles